Theriva™ biologics announces positive topline data from investigator sponsored phase 1 trial of intravitreal vcn-01 in pediatric patients with refractory retinoblastoma

–phase 1 trial in collaboration with sant joan de dÉu-barcelona children's hospital (sjd) determined to have a positive outcome by the study monitoring committee–

TOVX Ratings Summary

TOVX Quant Ranking